Get the Stockscreener App
2.87
3.37%
-0.10
After Hours:
3.13
0.26
+9.06%
Transcode Therapeutics Inc stock is traded at $2.87, with a volume of 38,953.
It is down -3.37% in the last 24 hours and down -65.83% over the past month.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
See More
Previous Close:
$2.97
Open:
$2.9
24h Volume:
38,953
Relative Volume:
0.62
Market Cap:
$3.04M
Revenue:
-
Net Income/Loss:
$-40.36M
P/E Ratio:
-0.059
EPS:
-48.648
Net Cash Flow:
$-21.40M
1W Performance:
-12.50%
1M Performance:
-65.83%
6M Performance:
-70.38%
1Y Performance:
-69.53%
1-Day Range:
$2.87
$3.00
1-Week Range:
$2.87
$3.4978
52-Week Range:
$2.87
$20.99
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Name
Transcode Therapeutics Inc
Sector
Industry
Phone
857-301-6857
Address
6 LIBERTY SQUARE, BOSTON
Compare RNAZ vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
2.87 | 3.14M | 0 | -40.36M | -21.40M | -48.65 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Transcode Therapeutics Inc Stock (RNAZ) Latest News
TransCode Therapeutics (RNAZ) Q4 2024 Earnings: Wider-than-Expected Loss of $150.64 Per Share Weighs on SharesEarnings Yield Spread - vinanet.vn
TransCode Therapeutics (NASDAQ: RNAZ) logs $24.5M loss and funding strain - Stock Titan
TransCode Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
TransCode Therapeutics (RNAZ) Holds Above $3.50 as Shares Grind Higher in Quiet SessionExhaustion Gap - vinanet.vn
TransCode Therapeutics (RNAZ) Advances 3.26% to $3.48, Approaching Key Resistance at $3.65Sector Neutral Pair - vinanet.vn
Transcode Therapeutics Inc (RNAZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Transcode Therapeutics Inc (RNAZ) Stock News Today - TradingKey
Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV - ACCESS Newswire
Why (RNAZ) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Major holder converts preferred shares at Transcode Therapeutics, Inc. (RNAZ) - stocktitan.net
Transcode Therapeutics (RNAZ) major holders disclose convertible preferred stake - Stock Titan
TransCode Therapeutics Updates Preferred Stock Governance Terms - The Globe and Mail
DEFJ lifts TransCode Therapeutics (RNAZ) stake to 83.9% after conversions - Stock Titan
TransCode Therapeutics (RNAZ) Retreats 2.7% to $4.62, Approaching Key Support ZoneDynamic Hedging - dars.gov.et
TransCode Therapeutics Q4 2024 Earnings: Wider-than-Expected Loss of -$150.64 Per Share Signals Ongoing Clinical-Stage Cash BurnCapex Guidance - vinanet.vn
RNAZ|Transcode Therapeutics Inc|Price:5.800|Chg%:-0.130 - TradingKey
Unleash Immuno Oncolytics (RNAZ holder) reports 9.94% TransCode Therapeutics stake - Stock Titan
Transcode Therapeutics Inc (RNAZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TransCode Therapeutics (RNAZ) holder moves toward controlling stake via conversions - Stock Titan
Transcode Therapeutics Inc (RNAZ) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
RNAZ|Transcode Therapeutics Inc|Price:5.930|Chg%:-1.170 - TradingKey
Transcode Therapeutics Inc (RNAZ) Balance Sheet - TradingKey
TransCode Therapeutics, Inc. Revenue Breakdown – NASDAQ:RNAZ - TradingView
RNAZ|Transcode Therapeutics Inc|Price:3.995|Chg%:+0.035 - TradingKey
Transcode Therapeutics Inc (RNAZ) Cash Flow - TradingKey
Transcode Therapeutics Inc (RNAZ) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Transcode Therapeutics Inc (RNAZ) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Transcode Therapeutics Inc (RNAZ) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Transcode Therapeutics Inc (RNAZ) Valuation: PE, PB & Fair Value Analysis - TradingKey
Transcode Therapeutics Inc (RNAZ) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Transcode Therapeutics Inc (RNAZ) Institutional Confidence - TradingKey
ON: ON Semiconductor Corp. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
TransCode Therapeutics (NASDAQ: RNAZ) investor conversion leads to 9.9% stake - Stock Titan
TransCode Therapeutics (RNAZ) Proxy Filing Summary - Quartr
TransCode Therapeutics, Inc. (RNAZ) 8-K: Key Nasdaq Approvals and Stockholder Vote Results July 2026 - Minichart
TransCode Therapeutics Inc. (RNAZ) Q4 2024 Earnings: Deep Losses on No Revenue as Cash Burn Persists - dars.gov.et
TransCode Therapeutics Shareholders Approve Key Capital Measures - TipRanks
TransCode Therapeutics (RNAZ) AGM 2026 Summary - Quartr
RNAZ Q4 2024 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Continues DevelopmentFinancial Data - Vinanet
TransCode Therapeutics Updates Preferred Stock Ownership Limits - The Globe and Mail
Form 13D/A TransCode Therapeutics For: 17 July By Investing.com - Investing.com South Africa
TransCode Therapeutics (RNAZ) investor to convert preferred stock toward 9.99% stake - Stock Titan
TransCode Therapeutics (NASDAQ: RNAZ) raises Series C ownership cap to 9.99% - Stock Titan
RNAZ Q4 2024 Earnings: Losses Widen as Clinical-Stage Biotech Continues R&D SpendBanking Earnings Report - vinanet.vn
Transcode Therapeutics Inc (NASDAQ: RNAZ) Share Price, RNAZ Stock News, RNAZ Share Price & Updates - Kalkine
Understanding Momentum Shifts in (RNAZ) - Stock Traders Daily
Price to earnings forward of TransCode Therapeutics, Inc. – NASDAQ:RNAZ - TradingView
Enterprise value to EBIT forward of TransCode Therapeutics, Inc. – NASDAQ:RNAZ - TradingView
Price to book forward of TransCode Therapeutics, Inc. – NASDAQ:RNAZ - TradingView
Enterprise value to EBITDA forward of TransCode Therapeutics, Inc. – NASDAQ:RNAZ - TradingView
Price to sales forward of TransCode Therapeutics, Inc. – NASDAQ:RNAZ - TradingView
Transcode Therapeutics Inc Stock (RNAZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
1.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):